ThromboGenics and BioInvent Start Phase II Trial of TB-402, an Anticoagulant for Deep Vein Thrombosis (DVT) Prophylaxis
Trial to assess the benefits of partial Factor VIII inhibition in patients undergoing knee replacement surgery
24-Feb-2009 -
ThromboGenics NV and co-development partner BioInvent International announce that the first patient has been enrolled in the Phase II trial with their long-acting anticoagulant TB-402 for the prophylaxis of Deep Vein Thrombosis (DVT) following orthopaedic surgery. TB-402, which is given as a ...
anticoagulants
deep vein thrombosis
surgery
+1